It is known that transient receptor potential cation channel subfamily V member 3 (TRPV3) is crucial for the modulation of skin homeostasis by regulation of Ca2+.
Scientists at Shanghai Synergy Pharmaceutical Sciences Co. Ltd. and Zhejiang Huahai Pharmaceutical Group Co. Ltd. have synthesized non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, inflammatory bowel disease (IBD) and lupus erythematosus.
Inhibition of OX40 is known to induce and maintain responses in moderate to severe atopic dermatitis (AD). Astria Therapeutics Inc. and Ichnos Sciences Inc. are developing STAR-0310, a YTE-modified (M252Y/S254T/T256E) monoclonal antibody targeting OX40.
A proprietary Src homology 2 (SH2) platform of integrated technologies was applied for the discovery of REX-7117 and REX-5376, two highly potent, selective and orally available SH2 domain-targeting STAT3 inhibitors.
Psoriasis is an inflammatory skin disease in which lipid metabolism is often dysregulated. ATP-citrate synthase (ACLY) is known to play a key role in lipid metabolism, but its involvement in psoriasis is not well understood.
Kinesin-like protein KIFC1 plays a role in the clustering of centrosomes in cancer cells and is being investigated in some types of cancer, concretely in melanoma.
RSS
